Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.
INTRODUCTION: In randomly assigned studies with EGFR TKI only a minor proportion of patients with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform EGFR and KRAS mutation analysis in non-squamous NSCLC. We explored tumor biopsy quality offered for mutation testing, dif...
Main Authors: | Gerald S M A Kerner, Ed Schuuring, Johanna Sietsma, Thijo J N Hiltermann, Remge M Pieterman, Gerard P J de Leede, John W G van Putten, Jeroen Liesker, Tineke E J Renkema, Peter van Hengel, Inge Platteel, Wim Timens, Harry J M Groen, CTMM Air Force Consortium |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3726644?pdf=render |
Similar Items
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)
by: Ke Xu, et al.
Published: (2019-04-01)
Similar Items
-
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
by: Paul van derLeest, et al.
Published: (2021-11-01) -
Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
by: H. C. Donker, et al.
Published: (2023-04-01) -
Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
by: Bart Koopman, et al.
Published: (2022-03-01) -
Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
by: Vincent D. de Jager, MD, et al.
Published: (2024-12-01) -
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)